Anti-CD137 and PD-1/PD-L1 Antibodies En Route toward Clinical Synergy
Pérez-Ruiz E (1,2,3), Etxeberria I (1,2), Rodriguez-Ruiz ME (1,2,4,5), Melero I (6,2,4,5).
(1) Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.
(2) Navarra Institute for Health Research (IDISNA), Pamplona, Spain.
(3) Servicio de Oncología Médica, Hospital Costa del Sol, Marbella, Spain.
(4) Servicio de Inmunología e Inmunoterapia, Clínica Universidad de Navarra, Pamplona, Spain.
(5) CIBERONC (Centro de Investigación Biomédica en red de Oncología), Madrid, Spain.
(6) Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain
Magazine: Clinical Cancer Research
Date: Sep 15, 2017Immunology [SP] Radiation Oncology
T-cell costimulation and coinhibition can be respectively exploited by blocking and agonist mAbs. Both strategies can be synergistically combined in mouse models.
Early clinical results from combinations of anti-PD-1 mAbs in conjunction with agonist anti-CD137 (4-1BB) mAbs show excellent safety and promising efficacy. Clin Cancer Res; 23(18); 5326-8. ©2017 AACRSee related article by Tolcher et al., p. 5349.
CITATION Clin Cancer Res. 2017 Sep 15;23(18):5326-5328. doi: 10.1158/1078-0432.CCR-17-1799. Epub 2017 Aug 8.
you mayBE INTERESTED
The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.
The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.
Learn why we are different from other healthcare centers. Quality, speed, comfort and results.